Evidence map›Paper›PMID 25311179›Full record

ArticleInternational journal of pharmaceutics2014

Intranasal delivery of liposomal indole-3-carbinol improves its pulmonary bioavailability.

Jung Min Song, Ameya R Kirtane, Pramod Upadhyaya, Xuemin Qian, Silvia Balbo, Fitsum Teferi, Jayanth Panyam, Fekadu Kassie

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Intranasal Iloprost Prevents Tumors in a Murine Lung Carcinogenesis Model.Cancer prevention research (Philadelphia, Pa.) · 2022
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Jung Min SongMasonic Cancer Center, University of Minnesota, MN, USA.
Ameya R KirtaneDepartment of Pharmaceutics, University of Minnesota, MN, USA.
Pramod UpadhyayaMasonic Cancer Center, University of Minnesota, MN, USA.
Xuemin QianMasonic Cancer Center, University of Minnesota, MN, USA.
Silvia BalboMasonic Cancer Center, University of Minnesota, MN, USA.
Fitsum TeferiMasonic Cancer Center, University of Minnesota, MN, USA.
Jayanth PanyamMasonic Cancer Center, University of Minnesota, MN, USA; Department of Pharmaceutics, University of Minnesota, MN, USA.
Fekadu KassieMasonic Cancer Center, University of Minnesota, MN, USA; College of Veterinary Medicine, University of Minnesota, MN, USA. Electronic address: kassi012@umn.edu.
University of Minnesota · USPharmac · NZUniversity of Veterinary Medicine · HU

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Douglas Yee · 1998 to 2026
$100.4M
Lung carcinogenesis: Chemoprevention by Indole-3-carbinolR01CA128801 · NCI · UNIVERSITY OF MINNESOTA · PI KASSIE, FEKADU · 2009 to 2013
$1.2M
Diindolylmethane:Inhibition of lung squamous cell carcinoma by targeting Akt.R21CA164235 · NCI · UNIVERSITY OF MINNESOTA · PI KASSIE, FEKADU · 2012 to 2013
$354k
NCI NIH HHS P30 CA077598NCI NIH HHS R01 CA128801NCI NIH HHS R01CA-128801NCI NIH HHS R21 CA164235
6 · The paper itself

Abstract

Indole-3-carbinol (I3C), a constituent of commonly consumed Brassica vegetables, has been shown to have anticancer effects in a variety of preclinical models of lung cancer. However, it has shown only limited efficacy in clinical trials, likely due to its poor oral bioavailability. Intranasal administration of I3C has the potential to enhance the pulmonary accumulation of the drug, thereby improving its availability at the target site of action. In this study, we developed a liposomal formulation of I3C and evaluated its lung delivery and chemopreventive potential in tobacco smoke carcinogen [4-(methylnitro-samino)-1-(3-pyridyl)-1-butanone (NNK)]-treated mice. Intranasal administration of I3C liposomes led to a ∼100-fold higher lung exposure of I3C than the oral route of administration. Further, intranasal delivery of liposomal I3C led to a significant reduction (37%; p<0.05) in the levels of the DNA adduct formation induced by NNK treatment. Liposomal I3C also significantly increased (by 10-fold) the expression of CYP1A1, a cytochrome P450 enzyme known to increase the detoxification of chemical carcinogens by enhancing their metabolism. Overall, our findings demonstrate that intranasal administration of liposomal I3C has the potential to significantly improve the efficacy of I3C for lung cancer chemoprevention.

Indexed as

Drug Delivery SystemsAdministration, IntranasalAdministration, OralAnimalsAnticarcinogenic AgentsBiological AvailabilityCarcinogensCytochrome P-450 CYP1A1FemaleGene Expression Regulation, EnzymologicIndolesLiposomesLungLung NeoplasmsMiceNitrosamines4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanoneAnticarcinogenic AgentsCarcinogensCytochrome P-450 CYP1A1indole-3-carbinolIndolesLiposomesNitrosamines4-(Methylnitro-samino)-1-(3-pyridyl)-1-butanone4-(Methylnitro-samino)-1-(3-pyridyl)-1-butanone (PubChem CID: 47,289)Cytochrome P450 1A1Diindolylmethane (PubChem CID: 3071)DNA adductIndole-3-carbinolIndole-3-carbinol (PubChem CID: 3712)LiposomesO(6)-Methylguanine DNA adduct

Identifiers

PMID25311179
PMCPMC4268270
OpenAlexW2092618638

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.